title: [Pharma-clinics. Drug of the month. Premelle (conjugated estrogens + medroxyprogesterone].
abstract: Premelle, commercialised by Wyeth-Lederle, is a combination of conjugated estrogens 0.625 mg and medroxyprogesterone acetate 5 mg which is indicated in the treatment of menopause-associated problems, among which vasomotor symptoms, atrophic vaginitis and/or urethritis, and in the prevention and treatment of post-menopausal osteoporosis. It is presented in two formulations, Premelle cyclic 5 and Premelle 5. The former, in which the progestagen is only given during the last 14 out of 28 days of the treatment cycle, is accompanied by regular bleeding and thus preferably indicated during perimenopause whereas the latter, in which the progestagen is given continuously and results in amenorrhea, is mostly indicated after menopause in order to improve long-term compliance.
authors.affiliation: Université de Liège.
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
mesh_terms: D004338:Drug Combinations; D015914:Estrogen Replacement Therapy / Q000379:methods*; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008875:Middle Aged; D017697:Premenopause / Q000187:drug effects*; D045167:Progesterone Congeners / Q000627:therapeutic use*
chemical_list: D004338:Drug Combinations; D004966:Estrogens, Conjugated (USP); D045167:Progesterone Congeners; D008525:Medroxyprogesterone
vernacular_title: Pharma-clinics. Le médicament du mois. Premelle (oestrogènes conjugués + médroxyprogestérone).